Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ironwood Pharmaceuticals Inc IRWD

Healthcare Biotechnology
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of... see more

Recent & Breaking News (NDAQ:IRWD)

Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019

Business Wire May 9, 2019

Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

Business Wire May 7, 2019

Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

Business Wire May 2, 2019

Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call

Business Wire April 18, 2019

Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

Business Wire April 16, 2019

Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company

Business Wire April 1, 2019

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

Business Wire March 14, 2019

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

Business Wire March 7, 2019

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

Business Wire March 4, 2019

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

Business Wire February 26, 2019

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

Business Wire February 21, 2019

The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Benzinga.com  February 13, 2019

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

Business Wire February 13, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Benzinga.com  February 10, 2019

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

Business Wire January 28, 2019

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

Business Wire January 28, 2019

Investor Expectations to Drive Momentum within Hercules Capital, Alexandria Real Estate Equities, Ironwood Pharmaceuticals, 22nd Century Group, BorgWarner, and Forestar Group — Discovering Underlying Factors of Influence

GlobeNewswire January 25, 2019

Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation

Business Wire January 24, 2019

Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials

Business Wire January 23, 2019

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C

Business Wire January 15, 2019